AMPLI Amplitude Surgical

• Consolidated sales of €48.1 million, +3.9% at constant exchange rates
• Sales from knee and hip activity stable, -0.3% at constant exchange rates
• Further growth in Novastep’s activity, +33.1% at constant exchange rates

Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME plans), a leading French player on the surgical technology market for lower-limb orthopedics, announces its sales for the first half of its 2021-22 financial year.

Olivier Jallabert, Amplitude Surgical’s CEO, commented: “During the first half of our 2021-22 financial year, Amplitude Surgical recorded a 3.9% increase in sales at constant exchange rates. Knee and hip activity was stable compared with the previous year and continues to be negatively affected by the public health situation associated with the COVID-19 pandemic, with further health restrictions and cancelled operations as well as the reduced availability of operating rooms and medical staff. Novastep, meanwhile, has continued its development and now accounts for approximately 16.4% of the Group’s total sales, with growth of almost 33% over the period.”

Sales by activity

H1 2021-22 sales

 

31/12/2021

 

31/12/2020

 

Change at current exchange rates

 

Change at constant exchange rates

In thousands of euros - IFRS

 

 

 

 

Knee and hip activity

 

40,187

 

40,072

 

0.3%

 

-0.3%

Feet and ankles (Novastep)

 

7,912

 

5,838

 

35.5%

 

33.1%

Total

 

48,099

 

45,910

 

4.8%

 

3.9%

Q2 2021-22 sales

 

31/12/2021

 

31/12/2020

 

Change at current exchange rates

 

Change at constant exchange rates

In thousands of euros - IFRS

       

Knee and hip activity

 

23,150

 

20,892

 

10.8%

 

10.3%

Feet and ankles (Novastep)

 

4,760

 

3,435

 

38.6%

 

34.7%

Total

 

27,910

 

24,327

 

14.7%

 

13.7%

In the first half of its 2021-22 financial year (from July to December 2021), Amplitude generated sales of €48.1 million, up 4.8% in actual terms and 3.9% at constant exchange rates.

• Knee and hip activity was stable, with sales up 0.3% in actual terms and down 0.3% at constant exchange rates. Following a first quarter that was down on the previous year, notably impacted by lower operating room availability in France, the second quarter saw an upturn with growth of 10.3%, with fewer restrictions associated with the public health situation than the previous year. Nevertheless, the health situation and reduced availability of operating rooms and medical personnel are continuing to have a considerable negative impact on activity;
• Novastep, innovative solutions for foot and ankle surgery, generated strong growth over the half with sales totaling €7.9 million (+33.1% at constant exchange rates), driven by the United States. Novastep’s activity now accounts for 16.4% of total Group sales.

Sales by geographical region

H1 2021-22 sales

 

31/12/2021

 

31/12/2020

 

Change at current exchange rates

 

Change at constant exchange rates

In thousands of euros - IFRS

 

 

 

 

France

 

30,502

 

29,615

 

3.0%

 

3.0%

International

 

17,597

 

16,295

 

8.0%

 

5.6%

o/w subsidiaries

 

13,825

 

12,457

 

11.0%

 

7.9%

o/w distributors

 

3,771

 

3,839

 

-1.7%

 

-1.7%

Total

 

48,099

 

45,910

 

4.8%

 

3.9%

Q2 2021-22 sales

 

31/12/2021

 

31/12/2020

 

Change at current exchange rates

 

Change at constant exchange rates

In thousands of euros - IFRS

 

 

 

 

France

 

18,241

 

15,468

 

17.9%

 

17.9%

International

 

9,669

 

8,859

 

9.1%

 

6.4%

o/w subsidiaries

 

7,550

 

6,938

 

8.8%

 

5.3%

o/w distributors

 

2,119

 

1,921

 

10.3%

 

10.3%

Total

 

27,910

 

24,327

 

14.7%

 

13.7%

By geographical region, sales evolved as follows:

• On the French market, all in all Amplitude Surgical’s activities recorded sales growth of 3.0% over the last half to €30.5 million, representing 63.4% of total Group sales. Activity is continuing to be negatively affected by the public health situation associated with COVID-19, the posted growth being primarily due to the pandemic’s different level of impact between the two years;
• The Group’s international activity generated sales of €17.6 million, up 8.0% in actual terms and 5.6% at constant exchange rates thanks to international subsidiaries. The Group’s subsidiaries recorded growth of 7.9% at constant exchange rates to €13.8 million thanks to the considerable increase in Novastep’s foot and ankle activity in the United States. Activity with the Group’s distributors fell by 1.7%, with sales totaling €3.8 million;
• Amplitude Surgical’s direct business (French market and international subsidiaries), which accounted for almost 92% of the Group’s total sales, generated growth of 4.5% at constant exchange rates.

Next financial press release H1 2021-22 results, on Wednesday March 23, 2022, after market.

About Amplitude Surgical Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2021, Amplitude Surgical had a workforce of 443 employees and recorded sales of nearly 95.5 million euros.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220216005961/en/

Amplitude Surgical Dimitri Borchtch CFO finances@amplitude-surgical.com +33 (0)4 75 41 87 41

NewCap Investor Relations Mathilde Bohin/Thomas Grojean amplitude@newcap.eu +33 (0)1 44 71 94 94

NewCap Media Relations Nicolas Merigeau amplitude@newcap.eu +33 (0)1 44 71 94 98